MedTrace Logo

Mucormycosis in COVID-19

NCT04935463 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 728

Last updated 2023-04-18

No results posted yet for this study

Summary

The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge. There is very little known about the risk factors, patterns and complications of mucormycosis as it occurs either during the infection or treatment phase of the novel coronavirus (COVID-19). In light of this emerging epidemic within a pandemic, it is of time sensitive importance to obtain a better understanding of the risk factors and outcomes of this fatal complication

Conditions

  • Covid19
  • Mucormycosis
  • Aspergillosis
  • Candida Infection

Sponsors & Collaborators

  • Medanta Institute Delhi

    collaborator UNKNOWN

  • AIIMS Patna

    collaborator UNKNOWN

  • HCG Oncology Bangalore

    collaborator UNKNOWN

  • NSCB Jabalpur

    collaborator UNKNOWN

  • Montefiore Medical Center

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2022-03-01
Completion
2022-03-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04935463 on ClinicalTrials.gov